Johnson & Johnson (JNJ)
Johnson & Johnson - Johnson & Johnsons INLEXZO™(gemcitabine intravesical system) delivers 74 percent disease-free survival at one year in BCG-unresponsive, high-risk, papillary-only NMIBC
Johnson & Johnson - Johnson & Johnsons INLEXZO™(gemcitabine intravesical system) delivers 74 percent disease-free survival at one year in BCG-unresponsive, high-risk, papillary-only NMIBC
📉 **NEGATIVE** • Medium confidence analysis (67%) • Mild negative signal • Limited downside risk **Sentiment:** Negative (5%) **Content type:** General